对儿科卫生技术评估中的挑战进行范围审查,重点关注制药干预措施
Nora Hutchinson1,2, Lauren S Otterman1, Paul A Bain3
1Multi-Regional Clinical Trials Center of Brigham and Women's Hospital and Harvard, Boston, MA, USA.
International journal of technology assessment in health care
|October 16, 2025
概括
由于儿童独特的社会地位和数据限制,进行儿科健康技术评估 (HTA) 是一个挑战. 需要创新的方法来解决儿科HTA中的这些复杂性.
科学领域:
- 医疗技术评估 (HTA) 是指对医疗技术进行评估.
- 儿科健康 儿科健康
- 药物干预 药物干预
背景情况:
- 儿科卫生技术评估 (HTA) 面临着独特的挑战.
- 评估适用于儿童的新技术,特别是药品,需要特别考虑.
- 现有的HTA框架可能无法充分应对儿科患者.
研究的目的:
- 综合有关儿科卫生技术评估 (HTA) 的文献.
- 识别和绘制儿童使用新技术评估的挑战.
- 专注于儿科HTA中的药物干预措施.
主要方法:
- 根据乔安娜·布里格斯研究所的方法进行的范围审查.
- 在多个数据库 (PubMed,Embase,Web of Science,EconLit) 和灰色文献中进行搜索.
- 纳入标准侧重于儿科的HTA挑战,不包括特定技术试验.
主要成果:
- 包括103份报告,包括期刊文章,摘要和指导方针.
- 关键的挑战包括儿童的社会地位和将他们纳入全民的HTA系统.
- 儿科HTA的不确定性源于数据限制和HTA机构不一致的指导.
结论:
- 儿科人口的异质性,长期结果和社会因素使儿科HTA复杂化.
- 目前的方法不足以解决儿科患者群体的独特需求.
- 创新策略对于有效的儿科健康技术评估至关重要.
相关概念视频
Pharmacokinetics in Pediatric Patients: Drug Excretion
209
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
209
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
241
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
241
Pharmacokinetics in Pediatric Patients: Drug Metabolism
191
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
191
Pharmacokinetics in Pediatric Patients: Drug Distribution
251
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
251
Drug Dosing: Infants and Children
250
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
250
Drug Administration and Therapy Phases: Overview
1.3K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.3K


